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Myeloproliferative neoplasms (MPN) include essential
thrombocythemia (ET), polycythemia vera (PV), and pri-
mary myeloﬁbrosis (PMF) and are established clonal
disorders 1. MPN diagnosis affects survival of individuals
as compared with matched populations. Concerning PMF,
survival is currently stratiﬁed on the basis of the Inter-
national Prognostic Scoring System (IPSS)2 and its var-
iants or on the most recent mutation-based MIPSS-703.
In post-PV MF and post-ET MF, namely secondary
myeloﬁbrosis (SMF), the MYSEC PM (Myeloﬁbrosis
Secondary to PV and ET-Prognostic Model), has been
recently developed to assess survival4. Epidemiological
data have revealed an advantage for women in surviving a
diagnosis of cancer compared with men5. Sex hormones
might play a role in the hematopoiesis and in the patho-
genesis of hematologic malignancies6. Concerning MPNs,
gender differences have been observed in terms of disease
distribution (higher prevalence of females in ET and of
males in PV), JAK2V617F allele burden (lower in
females)7, and numbers of homozygous mutant colonies
(larger in males)8.
In this study, we assessed the prognostic impact of
gender in the study population of the multicenter MYSEC
project including 684 SMF patients with driver mutational
status available. Diagnosis of SMF was performed between
1981 and 2015 and were locally reviewed according to the
International Working Group on Myeloproliferative
Neoplasm Research and Treatment criteria (IWG-MRT
2008)1. Molecular and genetic tests were performed as
previously described9,10. The study was approved by the
ethical committee of each institution and conducted in
accordance with the Declaration of Helsinki. Statistical
analyses considered clinical and laboratory data collected
at the time of progression to SMF. Wilcoxon rank sum
and Pearson’s chi-squared tests were performed to report
differences between the groups, whereas Kaplan–Meier
estimators, log-rank tests, and Cox regression models
were used for time-to-event analysis.
The ﬁrst observation we found is that diagnosis of ET
and PV occurred at younger age in females versus males
(median, 50 vs. 53 years, p= 0.027) and that age at the
time of SMF transformation was similar between the
genders (median 63 vs. 65 years, p= 0.23). This is in favor
of a slower progression of the diseases in females, as
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documented by a longer time to progression in SMF
(median 11.3 vs. 10.1 years, p= 0.015).
Table 1 outlines clinical and laboratory features at
diagnosis of SMF, stratiﬁed by gender. Overall, 328
patients (48%) were females and the female/male ratio was
0.92. The cohort consisted of 332 PET MF and 352 PPV
MF, of which 167 (50%) and 161 (46%) were females,
respectively (p= 0.23). In SMF, female sex was correlated
with higher platelet count (p= 0.041), smaller palpable
spleen (p= 0.016), and lower frequency of circulating
blasts ≥ 1% (p= 0.008). We found also a correlation with
lower hemoglobin levels (p= 0.036), but this was evident
only in younger women as a possible expression of a pre-
menopausal phase. Within the PET MF cohort, female sex
was signiﬁcantly associated with smaller palpable spleen
(p= 0.024) and lower frequency of circulating blasts ≥1%
(p= 0.027). Conversely, we did not ﬁnd gender differ-
ences within PPV MF cohort.
Driver mutational status within SMF females was JAK2
in 257 (78%), CALR in 47 (14%), MPL in 17 (5%), and
triple negative in seven females (TN, 2%). Within females
with PET MF, the distribution was as follows: 96 JAK2
(57%), 47 CALR (28%), 17 MPL (10%), 7 TN (4%).
Mutation frequency was similar in the two genders (p=
0.57). Furthermore, female gender frequency per genotype
was 46% in JAK2-pos PPV MF, 53% in JAK2-pos PET MF,
46% in CALR-pos, 57% in MPL-pos, and 37% in TN cases
without signiﬁcant differences with respect to male gen-
der (p= 0.9). Concerning cytogenetic proﬁle, abnormal-
ities have been described in 58 females and 58 males (36
vs. 32%, P= 0.41). Of interest, the rate of complex kar-
yotype (non monosomal) was lower in females versus
males (3 vs. 12, i.e. 2 vs. 7%, p= 0.03).
During a median follow-up of 3 years (range, 0.6–27.3),
67 (10%) thrombosis occurred with an incidence of 3.1/
100 patient-years and 2.4/100 patient-years in the female
and male groups, respectively without signiﬁcant differ-
ences (p= 0.32). In addition, the rate of fatal thrombosis
was superimposable. Concerning blast phase (BP), 52 (8%)
transformations occurred with an incidence of 1.8/100
patient-years and 2/100 patient-years in the female and
male groups, respectively (p= 0.88).
Death occurred in 168 (25%) patients. Overall survival
from diagnosis of SMF was better in female (median
values, 10.1 years, 95% CI: 8.1-NR) than in male patients
(8.1 years, 95% CI: 6.8-NR), with a hazard ratio (HR) of
0.68 (95% CI: 0.50–0.92; log rank test p= 0.013, Fig. 1).
The correlation that we found, remained statistically sig-
niﬁcant even after adjusting for age at SMF diagnosis (HR
0.71, 95% CI: 0.52–0.97; p= 0.03) with a Cox regression
model, was uninﬂuential (p= 0.3). Of note, female gender
retained a survival advantage, albeit with a weak statistical
signiﬁcance, even when added as a covariate to the
MYSEC-PM risk strata and type of diagnosis (PPV MF
and PET MF) (HR 0.72, 95% CI: 0.51–1.02; p= 0.06).
Taking into account earlier disease onset in females, a
multivariable analysis including age at diagnosis and
gender found that female sex still remains signiﬁcant (HR:
0.71, 95% CI: 0.52–0.97; p= 0.03).
The current study indicates that women are character-
ized by a slower progression from PV/ET to SMF, more
indolent phenotype at SMF (higher platelet count, lesser
degree of splenomegaly and of circulating blasts) and a
longer life expectancy than male counterpart. Survival
difference between men and women in the general
population is well recognized, and in cancer subset
shorter survival might be linked to host factors, such as
activity of sex steroid hormone pathway, occupational
exposures, and lifestyle factors, as already described5.
From a biological viewpoint, MPNs patients exhibit
decreased telomere length, more evident in men than in
women11. This is indicative of a lower genomic instability
in females during disease progression. Looking for gene
expression between genders in MPNs, a differential gene
expression in female patients as compared with male
patients has been reported with 235 genes differentially
regulated in women, vs. 571 genes differentially regulated
in men12. In our analysis, we found that women have a
lower rate of complex karyotype (non monosomal) as a
result of lesser genomic instability. The correlation
between complex karyotype and worse survival has been
recently documented in SMF10. This could add explana-
tions to the different survivals that we found between the
genders.
The impact of gender on clinical phenotype has been
recently investigated in ET and PMF, but never in SMF.
Tefferi et al.13 demonstrated that older women with ET
live longer than their male counterparts and that gender
might supersede thrombosis history as a risk variable for
overall survival. An analysis on 1109 PMF showed that
mild anemia, deﬁned as hemoglobin between 10 g/dl and
sex-adjusted lower limit of normal, independently pre-
dicted shortened survival in men, but not in women14.
The magnitude of difference in beneﬁt we found in term
of survival between genders (average HR of 0.68, meaning
32% reduction of the risk of death for women with respect
to men) seems clinically relevant and has some implica-
tions. The most practical is for the doctor/patient com-
munication at the time of diagnosis of SMF. The second is
for helping decision making in those areas where a case by
case decision is suggested. So far, new therapeutic
approaches in MPNs have not taken sex into considera-
tion. However, focusing on subgroup analysis of the
COMFORT trials, women receiving ruxolitinib have bet-
ter survival than men (HR: 0.70; 95% CI: 0.49–0.998)15,
this can eventually overbalance the overall drug results.
In conclusion, our study in SMF indicates that female
gender has a more indolent disease with a speciﬁc
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Table 1 Presenting clinical and laboratory features of 684 patients with secondary myeloﬁbrosis, stratiﬁed by gender
SMF PET-MF PPV-MF
Female Male P Female Male P Female Male P
Median age at diagnosis of
SMF
63 (30–96) 65 (25–89) 0.23 62 (30–93) 64 (25–84) 0.36 64 (34–96) 66 (38–89) 0.55
Median follow up, years (95%
CI)
2. 9 (0–27) 3 (0–19) 0.76 2.9 (0–14) 3.2 (0–17) 0.53 3.2 (0–27) 2.9 (0–19) 0.31
WBC median (range), x109/L 10 (1.7–97.3) 10.4
(1.1–98.4)
0.89 8 (1.9–97.3) 7.5 (1.1–86) 0.15 12.4
(1.7–88.7)
14 (3–98.4) 0.68
Hb median (range), x109/L 10.9 (5–15.7) 11.6
(5.4–15.7)







Hb, categorya, n (%) 0.001 0.014 0.001
Severe 11 (4) 23 (7) 8 (5) 19 (12) 3 (2) 4 (2)
Moderate 84 (27) 63 (19) 53 (32) 40 (25) 31 (21) 23 (13)
Mild 117 (38) 188 (56) 71 (43) 84 (52) 46 (31) 104 (60)
Normal 97 (31) 60 (18) 31 (19) 17 (11) 66 (45) 43 (25)
Over 2 (1) 0 (0) 1 (1) 0 (0) 1 (1) 0 (0)











Presence of circulating blast, n
(%)
65 (22) 102 (32) 0.008 29 (19) 47 (32) 0.01 36 (26) 55 (32) 0.24
Spleenb, median (range) 6 (0–34) 8 (0–27) 0.0016 4 (0–25) 5 (0–27) 0.024 8 (0–34) 10 (0–27) 0.57
Constitutional symptoms, n
(%)
135 (44) 150 (45) 0.73 57 (37) 56 (36) 0.97 78 (50) 94 (52) 0.77
Normal karyotypec, n (%) 101 (64) 122 (68) 0.41 58 (70) 60 (77) 0.31 43 (57) 62 (61) 0.57
Favorable karyotyped, n (%) 131 (85) 154 (87) 0.52 117 (70) 114 (69) 0.85 63 (85) 83 (83) 0.7
Driver mutational status, n (%)
JAK2 257 (79) 276 (78) 0.8 96 (58) 85 (52) 0.28 161 (100) 191 (100) 1
CALR 47 (14) 55 (15) 0.68 47 (28) 55 (33) 0.3
MPL 17 (5) 13 (4) 0.33 17 (10) 13 (8) 0.47
Triple negative 7 (2) 12 (3) 0.33 7 (4) 12 (7) 0.23
Time between ET/PV and SMF
(years)
11.3 (0–39) 10.1 (0–41) 0.0015 11.4 (0.4–35) 9.7 (0.3–30) 0.005 11.1 (0–39) 10.8 (0.4–41) 0.49
Thrombotic events post SMF,
n (%)
37 (11) 30 (8) 0.21 18 (11) 11 (7) 0.18 19 (12) 19 (10) 0.59
Leukemic transformation, n
(%)
25 (8) 27 (8) 0.98 15 (9) 15 (9) 0.97 10 (6) 12 (6) 0.98
Deaths, n (%) 66 (20) 102 (29) 0.028 26 (16) 43 (26) 0.037 40 (25) 59(31) 0.45
ET essential thrombocythemia, PV polycythemia vera, SMF secondary myeloﬁbrosis, PET MF post-essential thrombocythemia myeloﬁbrosis, PPV MF post-polycythemia
vera myeloﬁbrosis, WBC white blood cell count, Hb hemoglobin level, PLT platelet count
aNicolosi et al.14
bPalpable from the left costal margin
cCytogenetic information available in 339 patients
dFavorable karyotype: normal karyotype or sole or two abnormalities that do not include the unfavorable cytogenetic abnormalities (complex karyotype or sole or two
abnormalities that include +8, −7/7q-, i(17q), −5/5q-, 12p-, inv(3), or 11q23 rearrangement)
Bold font indicates signiﬁcant p–values
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phenotype and better prognosis. This ﬁnding ﬁnally led to
a more accurate deﬁnition of the natural history of the
disease and drove the attention toward a careful inter-
pretation of clinical trial results.
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